Compare OPK & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPK | VOR |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.4B |
| IPO Year | 2011 | 2021 |
| Metric | OPK | VOR |
|---|---|---|
| Price | $1.49 | $120.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $1.60 | ★ $45.33 |
| AVG Volume (30 Days) | ★ 4.3M | 773.6K |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $606,879,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.98 | $1.90 |
| 52 Week High | $1.73 | $49.95 |
| Indicator | OPK | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 62.44 | 60.10 |
| Support Level | $1.26 | $21.75 |
| Resistance Level | $1.55 | $24.34 |
| Average True Range (ATR) | 0.05 | 1.13 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 87.63 | 54.84 |
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.